Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter


TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential




Share Price Information for Reneuron (RENE)


Share Price: 205.00Bid: 202.00Ask: 210.00Change: 0.00 (0.00%)No Movement on Reneuron
Spread: 8.00Spread as %: 3.96%Open: 206.00High: 205.00Low: 205.00Yesterday’s Close: 205.00

Reneuron Group Plc Ord 1P

Reneuron is listed in the FTSE AIM All-Share
Reneuron is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
205.00
Share Price SpacerBid
202.00
Share Price SpacerAsk
210.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
53,316
Share Price SpacerOpen
206.00
Share Price SpacerHigh
205.00
Share Price SpacerLow
205.00
Share Price SpacerClose
205.00
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 31.80m £65.19m 3,000

52 Week High 330.00 52 Week High Date 29-APR-2019
52 Week Low 47.50 52 Week Low Date 19-FEB-2019

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
18 22,865 30,451 -3.680 -55.70 0.00 0.00


London South East Users info for Reneuron




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

25-Jun-19
16:35:14
205.00
3,000
Sell* 
202.00
210.00
6,150
UT 
Trade Type:
Uncrossing Trade

25-Jun-19
16:22:23
202.4001
1,668
Sell* 
202.00
210.00
3,376
Trade Type:
Ordinary

25-Jun-19
16:15:50
208.7999
2,500
Buy* 
202.00
210.00
5,220
Trade Type:
Ordinary




View more Reneuron trades >>

Directors Deals for Reneuron (RENE)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Apr-19Buy
Trade Notifier Information for ReNeuron Group
Christopher Evans held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Christopher Evans
228.7GBX10,000254605
11-Apr-19Buy
Trade Notifier Information for ReNeuron Group
John Edward Berriman held the position of Non-Executive Chairman at ReNeuron Group at the time of this trade.
 John Edward Berriman
225GBX80,00090434
11-Apr-19Buy
Trade Notifier Information for ReNeuron Group
Simon Christopher Cartmell held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Simon Christopher Cartmell
225.55GBX7,75815633
View more Reneuron directors dealings >>


PC01
Posts: 365
Opinion:No Opinion
Price:205.00
RE: conspiracies.....
Tue 18:48
i think you are spot on. No doubt our SP has been hammered by speculation of what Woodford may or may not do...or has or hasnt done...but if Reneuron does what it can do, then the SP will look after itself. Big pharma will not blink at paying a substantial premium if the company continues to produce the encouraging results that has given it such a good bounce (from an idiotically low level) this year...
toptiger
Posts: 24
Opinion:No Opinion
Price:203.50
conspiracies.....
Tue 13:13
come on rene_to_40p,no way reneuron will mention woodford unless another funjd takes over in which case standard rns about holdings, or a reshuffling of percentages creates a takeover or required bid for the company.first one possible, second highly unlikely from a fund (more likely pharma).also for the theory they are witholding results to let woodford out is plausible, i dont like the fact that it appears they are publishing next cohort at same time as results for year (unless i have that wrong), would be a funny coincidence that that is the point where they become known.....and if they are letting woodford out then he might also know the results in which case why would he get out ?too many conspiracy theories here, reneuron just do the science and thats it.....which they appear to be very good at.
RENE_to_40p
Posts: 95
Opinion:No Opinion
Price:203.50
RE: RP Trial
Tue 10:26
I suppose you're right Grizzly.

It's just going to be a bit weird to get an update and it not mention the elephant in the room which has wiped a third off the company's value (about £32 million quid).

But, as you say, I don't really know what they could say about it.
grizzlyb
Posts: 67
Opinion:No Opinion
Price:203.50
RE: RP Trial
Tue 10:14
I don't see what they could do besides acknowledge that Woodford has a problem, after all it's Woodford's problem, not ReNeuron's. Woodford might make private investors steer clear for a while but it will only affect the share price, it doesn't affect the business. As it's not business performance affecting the share price, I don't think they need to be dragged into it.
RENE_to_40p
Posts: 95
Opinion:No Opinion
Price:206.00
RP Trial
Tue 09:25
How long was it from treatment of the 1st group of patients to us receiving news of their condition compared to the time between the 2nd cohort being treated and now?

It seems to me that the company is deliberately delaying announcing an update because they must know by now how they have fared. I reckon they are waiting as long as they can to give Woodford as much time as possible to try to get his house in order and ease the selling pressure before announcing.

They'll surely have to say something on 11th July, as that should be a comprehensive business update which must surely include the latest positions on the RP and stroke trials. I'll be annoyed if they don't even acknowledge the Woodford debacle in that statement. It is of material interest for the business, its shareholders and potential investors.
View more share chat for Reneuron (RENE) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.